Plexus (PLXS) Q3 2026 Earnings Call Transcript

Plexus (PLXS) reported fiscal Q3 revenue of $1.31B (+28% YoY, +12% QoQ) with non-GAAP EPS of $2.32, topping guidance (range $2.02–$2.18) and non-GAAP operating margin of 6.3% at the top end of guidance. For fiscal Q4, the company guided revenue of $1.33B–$1.38B (+28% YoY at midpoint), non-GAAP EPS of $2.47–$2.63, and operating margin of 6.1%–6.5%, lifting the fiscal 2026 outlook to >20% revenue growth with margin >6%. Cash generation improved materially, with a record 62-day cash cycle and free cash flow expected to return to >$100M in fiscal 2027, alongside $20.6M in share repurchases (about $21M remaining authorization).

Analysis

PLXS is turning into a capacity-constrained execution story, not a cyclical recovery story. The key second-order effect is that the company is converting demand visibility into share gains because it can still ship through a tightening supply chain; that should pressure smaller EMS peers with weaker planning systems and less balance-sheet flexibility, while benefiting adjacent suppliers in semicap, defense electronics, and data-center power/thermal subsystems.

The near-term risk is that the market may overweight the improved top line and underweight the fact that FY26 FCF is still being pulled forward into working capital and higher interest expense. Over the next 1-3 months, the stock likely trades on whether investors believe the 2027 bridge is real; if the next two quarters show stable margin >6% and cash cycle stays in the low-60s, PLXS can re-rate, but if inventory builds faster than customer-funded preplacements, the multiple should compress.

Contrarian view: consensus may be missing that this is less about one strong quarter and more about a durable operating model inflection in high-complexity manufacturing. The market could be underestimating the optionality from defense/unmanned, data-center power, and semi-cap share gains, which can extend growth even if healthcare normalizes; the falsifier is any sign that A&D wins fail to convert to revenue or that FY27 margin expansion stalls below 6%.

Trade-wise, the cleanest expression is long PLXS on post-earnings weakness versus an EMS basket, because the setup is better operating leverage plus better working capital discipline, not just higher demand. For a more tactical expression, buy a 1-3 month call spread only if the stock re-tests the pre-print gap and holds, since the main downside is not demand but valuation if cash conversion disappoints. If management revises FY27 FCF or capex higher, fade the move quickly; that would indicate growth is consuming too much capital for the current multiple.

Key Decisions for Investors

• Buy PLXS on any post-earnings pullback; use a 1-3 month horizon and treat $6%+ operating margin / low-60s cash cycle as the validation point for holding the position.
• Pair trade: long PLXS / short a lower-quality EMS basket (e.g., FLEX + SANM) to isolate execution and working-capital advantage; thesis weakens if PLXS margin guidance slips below 6%.
• If the stock gaps up sharply, use a 1-3 month call spread instead of outright stock to capture the re-rate while limiting risk from a working-capital/FCF disappointment.
• Set an alert for any FY26 or FY27 FCF commentary deterioration; if management signals sustained cash burn beyond FY26, reduce exposure because the market will likely de-rate the multiple despite growth.